Press release
Respiratory Syncytial Virus (RSV) Market to Reach USD 5.6 Billion by 2034
Respiratory Syncytial Virus
Pune, India, November 2025 - According to Exactitude Consultancy, the Respiratory Syncytial Virus (RSV) Market is projected to reach USD 5.6 billion by 2034, growing at a CAGR of 8.1% from 2025 to 2034. The surge in demand for preventive and therapeutic solutions against RSV is being driven by rising awareness, expanded immunization programs, and new antiviral approvals from leading pharmaceutical players.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72688
RSV remains a significant cause of respiratory illness among infants, immunocompromised patients, and the elderly, prompting major investments in both monoclonal antibody and vaccine development.
Key Takeaways
• Market Size: USD 2.6 billion in 2024 → projected USD 5.6 billion by 2034
• CAGR: 8.1% (2025-2034)
• Key Growth Drivers: Increasing disease prevalence, early diagnosis, vaccine commercialization, and improved healthcare access
• Leading Companies: Pfizer Inc., GSK plc, AstraZeneca, Sanofi, Moderna, Merck & Co., Johnson & Johnson, and Novavax
• Emerging Regions: North America leads with over 40% share; Asia-Pacific shows fastest growth (CAGR > 9%)
Market Story
Recent vaccine approvals have been game changers for the RSV market. In 2023, GSK's Arexvy became the first FDA-approved RSV vaccine for older adults, followed by Pfizer's Abrysvo for both adults and pregnant women to protect infants through maternal immunization. These approvals mark a new era of preventive care against RSV-related hospitalizations.
In parallel, AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has gained traction globally as an alternative to palivizumab, offering broader protection for infants through a single dose per RSV season. The integration of AI-based epidemiology tracking and digital surveillance systems by healthcare agencies is also improving early outbreak detection.
Market Segmentation
By Drug Type:
• Monoclonal Antibodies (Palivizumab, Nirsevimab)
• Vaccines (Arexvy, Abrysvo, mRNA-based candidates)
• Antivirals (Ribavirin, Fusion Inhibitors)
By Route of Administration:
• Intramuscular
• Intravenous
• Oral
By End User:
• Hospitals
• Pediatric Clinics
• Specialty Centers
By Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
Explore Full Report here: https://exactitudeconsultancy.com/reports/72688/respiratory-syncytial-virus-market
Recent Developments
• September 2025: Pfizer announced global expansion of Abrysvo supply under public vaccination programs in the U.S. and Europe.
• August 2025: Moderna reported Phase 3 success of its mRNA-1345 RSV vaccine with over 82% efficacy in adults over 60.
• June 2025: GSK entered a collaboration with CureVac for next-generation mRNA RSV candidates.
• April 2025: AstraZeneca and Sanofi initiated WHO-supported campaigns in low- and middle-income countries for Beyfortus distribution.
Expert Insight
"The RSV vaccine landscape is witnessing one of the fastest adoptions ever recorded in adult and maternal immunization history," said Dr. Elisa Torres, Senior Analyst at Exactitude Consultancy. "With dual protection strategies combining maternal vaccination and pediatric antibody administration, the global burden of RSV is expected to decline significantly by 2030."
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72688
Market Drivers
• Rising RSV infection rates among infants and the elderly
• Expanding immunization recommendations and government funding
• Global clinical trials pipeline with >60 active vaccine/antiviral candidates
• Technological advancements in RNA platforms and monoclonal antibody engineering
Forecast and Regional Outlook
North America leads due to strong regulatory support and early commercialization, followed by Europe where healthcare systems are rapidly integrating RSV screening in neonatal programs. Asia-Pacific, especially China and India, is emerging as a key growth region due to high birth rates and expanding healthcare expenditure.
Government Initiatives
• CDC (U.S.) launched nationwide RSV vaccination campaigns for adults over 60 in 2024.
• European Medicines Agency (EMA) fast-tracked RSV vaccine approvals under its "PRIME" scheme.
• India's ICMR announced RSV surveillance inclusion under its Integrated Disease Surveillance Programme (IDSP) in 2025.
Conclusion
The RSV market is poised for exponential growth over the next decade, supported by unprecedented vaccine rollouts, antibody innovation, and proactive government initiatives. As awareness expands and production scales up, manufacturers and healthcare systems worldwide are aligned toward reducing RSV-related morbidity and mortality rates globally.
This report is also available in the following languages : Japanese (呼吸器合胞体ウイルス市場), Korean (호흡기 세포융합 바이러스 시장), Chinese (呼吸道合胞病毒市场), French (Marché du virus respiratoire syncytial), German (Markt für das Respiratorische Synzytialvirus), and Italian (Mercato del virus respiratorio sinciziale), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72688/respiratory-syncytial-virus-market#request-a-sample
Related Reports
mRNA Vaccine and Therapeutics Raw Material Market
https://exactitudeconsultancy.com/reports/65932/mrna-vaccine-and-therapeutics-raw-material-market
mRNA Therapy Market
https://exactitudeconsultancy.com/reports/68833/mrna-therapy-market
Messenger RNA (mRNA)-based Vaccines and Therapeutics Market
https://exactitudeconsultancy.com/reports/70950/messenger-rna-mrna-based-vaccines-and-therapeutics-market
Antiphospholipid Syndrome Market
https://exactitudeconsultancy.com/reports/71298/antiphospholipid-syndrome-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Respiratory Syncytial Virus (RSV) Market to Reach USD 5.6 Billion by 2034 here
News-ID: 4257569 • Views: …
More Releases from Exactitude Consultancy
Oriented Perforating System Market Expands as Oil & Gas Producers Demand 2034
Sub-headline: Growing investments in directional drilling, unconventional reservoirs, and high-precision well stimulation technologies are driving the oriented perforating system market through 2034.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/75135
Introduction
The global Oriented Perforating System Market is witnessing strong growth as oil & gas operators prioritize precision perforation to maximize reservoir productivity, reduce formation damage, and enhance wellbore connectivity. Oriented perforating systems-engineered to align perforation tunnels toward the optimal reservoir direction-are…
Automotives Infrared Cores Market Accelerates as ADAS, Night Vision Systems, and …
Sub-headline: Growing demand for thermal imaging, enhanced driver assistance systems, and smart safety features is fueling strong growth in the automotive infrared cores market through 2034.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/75133
Introduction
The global Automotives Infrared Cores Market is witnessing rapid expansion as vehicles increasingly adopt advanced infrared imaging technologies to improve visibility, safety, and autonomous navigation. Infrared cores-compact thermal imaging modules integrated into ADAS, night vision systems, pedestrian…
Safeguards for Passenger Transfer Area Market Grows 2034
Sub-headline: Increasing global investments in public transport infrastructure, rising passenger traffic, and growing focus on automated safety systems are driving the safeguards for passenger transfer area market through 2034.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/75131
Introduction
The global Safeguards for Passenger Transfer Area Market is witnessing significant growth as transport authorities, airports, metro stations, and bus terminals enhance safety, accessibility, and operational efficiency in high-traffic areas. Safeguards-such as platform screen…
Titanium Catalyst for Polyester Market Expands ,Demand Increases Globally
Sub-headline: Rising PET bottle production, sustainability-driven adoption of eco-friendly catalysts, and advances in high-purity polyester processing are driving strong growth in the titanium catalyst for polyester market through 2034.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/75129
Introduction
The global Titanium Catalyst for Polyester Market is witnessing steady expansion as manufacturers shift from antimony-based catalysts to titanium-based alternatives for safer, cleaner, and more efficient polyester production. Titanium catalysts are preferred for PET…
More Releases for RSV
The Rise In The Prevalence Of RSV Infection : A Key Catalyst Accelerating Global …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Respiratory Syncytial Virus (RSV) Therapeutics Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market encompassing therapeutics for respiratory syncytial virus (rsv) has witnessed substantial, rapid expansion lately, projected to increase its valuation from $1.6 billion in 2024 to $2 billion just one year later…
The Rise In The Prevalence Of RSV Infection : Transformative Forces Shaping the …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Respiratory Syncytial Virus (RSV) Therapeutics Industry Market Size Be by 2025?
The market size for therapeutics treating the respiratory syncytial virus (RSV) has seen significant expansion in the past few years. It is expected to surge from $1.6 billion in 2024 to $2 billion in 2025,…
RSV Vaccine Market To Reach 731 million by 2040, Due To Increasing Awareness on …
According to our latest market report "RSV Vaccine Market, Till 2040 by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions and Leading Players", the RSV Vaccine market size is projected to reach USD 731 million by 2040 from USD 1,149 million in current year, during the forecast period.
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/rsv-vaccine-market/request-quote.html
In the dynamic landscape of preventive therapies for respiratory…
Global RSV Diagnostic Products Market Size & Trends
According to a new market research report published by Global Market Estimates, the global RSV diagnostic products market is expected to grow at a CAGR of 11.4% from 2023 to 2028.
Ongoing advancements in diagnostic technologies, specifically PCR and rapid point-of-care testing, play a crucial role. These advancements offer heightened accuracy, faster results, and increased accessibility, enabling prompt and precise identification of RSV infections.
Browse 147 Market Data Tables and 115 Figures…
Respiratory Syncytial Virus (RSV) Therapeutics Market Size to Reach USD 9080.84 …
Respiratory Syncytial Virus (RSV) Therapeutics Market Scope & Overview
Respiratory Syncytial Virus (RSV) Therapeutics Market size was USD 1040.65 Million in 2022 and is expected to Reach USD 9080.84 Million by 2030 and grow at a CAGR of 31.1% over the forecast period of 2023-2030.
The Respiratory Syncytial Virus (RSV) Therapeutics market is a vibrant, fiercely competitive sector that is essential to digital marketing. The demand for effective has increased as companies…
Respiratory Syncytial Virus (RSV) Therapeutics Market - Conquering RSV: Advancin …
Newark, New Castle, USA: The "Respiratory Syncytial Virus (RSV) Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Respiratory Syncytial Virus (RSV) Therapeutics Market: https://www.growthplusreports.com/report/respiratory-syncytial-virus-rsv-therapeutics-market/8519
This latest report…
